TDP-43-TRAF6 interaction-inhibiting peptide
TDP-43-TRAF6 interaction-inhibiting peptide has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jul 16, 2025: “TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration”.
1 paper studies it3 findingsUpdated
- 1 lab in 1 country
- Animals1
What did studies of TDP-43-TRAF6 interaction-inhibiting peptide find?
3Studies of TDP-43-TRAF6 interaction-inhibiting peptide measured 3 outcomes; the most studied are cognitive decline (1 study), movement disorders (1) and TDP-43 aggregation (1).
Cognitive decline
downin mice1
1 study
Cognitive decline
downin mice1
TDP-43-TRAF6 interaction-inhibiting peptide decreases cognitive decline in mice.
“alleviates movement disorders and cognitive decline in mouse models”
Animalsin mouse models
TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration
Molecular psychiatry
Movement disorders
downin mice1
1 study
Movement disorders
downin mice1
TDP-43-TRAF6 interaction-inhibiting peptide decreases movement disorders in mice.
“This peptide effectively reduces pathological TDP-43 aggregation in cells and alleviates movement disorders and cognitive decline in mouse models.”
Animalsin mouse models
TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration
Molecular psychiatry
TDP-43 aggregation
downin mouse cells1
1 study
TDP-43 aggregation
downin mouse cells1
TDP-43-TRAF6 interaction-inhibiting peptide decreases TDP-43 aggregation in mouse cells.
“This peptide effectively reduces pathological TDP-43 aggregation in cells and alleviates movement disorders and cognitive decline in mouse models.”
Cells
TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration
Molecular psychiatry